Tau-Targeted Immunotherapy for Alzheimer's Disease: Insight into Clinical Trials
Abstract
(ISSN 2573-4407)
OBM Neurobiology is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. By design, the scope of OBM Neurobiology is broad, so as to reflect the multidisciplinary nature of the field of Neurobiology that interfaces biology with the fundamental and clinical neurosciences. As such, OBM Neurobiology embraces rigorous multidisciplinary investigations into the form and function of neurons and glia that make up the nervous system, either individually or in ensemble, in health or disease. OBM Neurobiology welcomes original contributions that employ a combination of molecular, cellular, systems and behavioral approaches to report novel neuroanatomical, neuropharmacological, neurophysiological and neurobehavioral findings related to the following aspects of the nervous system: Signal Transduction and Neurotransmission; Neural Circuits and Systems Neurobiology; Nervous System Development and Aging; Neurobiology of Nervous System Diseases (e.g., Developmental Brain Disorders; Neurodegenerative Disorders).
OBM Neurobiology publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). Although the OBM Neurobiology Editorial Board encourages authors to be succinct, there is no restriction on the length of the papers. Authors should present their results in as much detail as possible, as reviewers are encouraged to emphasize scientific rigor and reproducibility.
Publication Speed (median values for papers published in 2023): Submission to First Decision: 7.5 weeks; Submission to Acceptance: 15.9 weeks; Acceptance to Publication: 7 days (1-2 days of FREE language polishing included)
Special Issue
Molecular Mechanisms of Alzheimer's Disease Pathogenesis
Submission Deadline: June 30, 2025 (Open) Submit Now
Guest Editor
R. M. Damian Holsinger, PhD, Senior Lecturer in Neuroscience
Head, Laboratory of Molecular Neuroscience and Dementia, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia.
Research interests: Ageing, Alzheimer's disease, Cell biology, Dementia, Molecular biology
About This Topic
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder afflicting individuals worldwide. Although the molecular underpinnings of the disease appear to be somewhat understood, there is a continuous flow of novel discoveries that are shedding new light on this century-old disease. Omics-based studies have revealed molecular signatures associated with various stages of the disease and could potentially lead to early diagnosis and treatment. The identification of risk factors continue to inform on lifestyle modifications that could stave off the disease. Novel animal models of the disease continue to provide pivotal information on molecular, cellular and biological aspects of disease onset, progression and treatment. Although treatment for the disease still appears to be the Achilles’ heel, advances on numerous fronts provide hope that an intervention, be it treatment or cure, is close at hand.
In this Special Issue, our aim is to curate articles from diverse areas of Alzheimer’s Disease (AD) research, culminating in a comprehensive resource that fosters a deeper and more nuanced understanding of this devastating disease.
Manuscript Submission Information
Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (neurobiology@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.
Welcome your submission!
Publication
Tau-Targeted Immunotherapy for Alzheimer's Disease: Insight into Clinical TrialsAbstract The use of immunotherapy as a therapeutic approach to Alzheimer's Disease (AD) is gaining rapid interest, with the primary goal of targeting abnormalities that impact neuronal viability through specific antibodies. Currently, clinical strategies focus intensively on targeting the two main pathologies associated with AD, beta-amyloid (A
|
TOP